Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)Stephanie M. Cushman, Andrew B. Nixon, Chen Jiang et al.|Clinical Cancer Research|2014Cited by 87
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving RegorafenibYingmiao Liu, Andrew B. Nixon, Jing Lyu et al.|Molecular Cancer Therapeutics|2020Cited by 30
Association of Tumor <i>HER3</i> Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal CancerJenny F. Seligmann, Michel Seymour, Ace J. Hatch et al.|JAMA Oncology|2017Cited by 29
Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance)Ace J. Hatch, Andrew B. Nixon, Alexander B. Sibley et al.|Cancer Medicine|2016Cited by 20
Genetic variation determines VEGF-A plasma levels in cancer patientsFederico Innocenti, Kouros Owzar, Chen Jiang et al.|Scientific Reports|2018Cited by 17